Laboratory Test	Result	reference range
Serum Creatinine	1 mg/dl (88.4 μmol/L)	0.5-1.1 mg/dL (44-97 μmol/L)
BUN	9 mg/dl. (3.2 mmol/L)	10-20 mg/dl. (3.6-7.1 mmol/L)
Sodium	136 mEq/L (136 mmol/L)	136 to 145 mEq/L (136 to 145 mmol/L)
Potassium	6.1 mEq/L (6.1 mmol/L)	3.5 to 5 mEq/L (3.5 to 5 mmol/L)

The nurse reviews the lab values.

What questions can the nurse ask the client based on the lab results? Select all that apply.

Here are the potential effects of each drug on captopril's blood pressure effects:

Losartan: Decrease - Losartan is an angiotensin receptor blocker (ARB) that can lower blood pressure. When used in combination with captopril (an ACE inhibitor), it may enhance the antihypertensive effects, potentially leading to an additive blood pressure-lowering effect.

Ibuprofen: Increase - Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can lead to sodium and water retention and potentially raise blood pressure. When combined with captopril, it may diminish captopril's blood pressure-lowering effects.

Amlodipine: No Effect - Amlodipine is a calcium channel blocker used to treat high blood pressure. It has a different mechanism of action than captopril and combining them typically does not interfere significantly with each other's effects.

Sulfa: No Effect - Sulfonamides (sulfa drugs) are antibiotics that generally do not directly impact blood pressure or interact with antihypertensive medications like captopril in terms of blood pressure effects.

Insulin lispro: No Effect - Insulin lispro is used to manage blood glucose levels in diabetes. While uncontrolled blood glucose can indirectly affect blood pressure, insulin lispro itself does not directly interact with captopril's blood pressure effects.

Please note that drug interactions can be complex, and individual responses may vary. It's crucial for the healthcare provider to monitor the patient's blood pressure and adjust medications as needed to achieve optimal control.

A. Unpleasant smell when using the medication:

While acetylcysteine has a distinctive odor, this is not the primary therapeutic response to expect. The odor is often described as unpleasant or sulfur-like.

B. Bronchodilation and wheezing:

Acetylcysteine is not primarily used for bronchodilation. It is used to thin mucus and facilitate its removal. Wheezing is not a common response to acetylcysteine.

When administering acetylcysteine via nebulization through an endotracheal tube to a client with pneumonia, the nurse should expect the following therapeutic response:

C. Increased sputum, requiring suctioning.

Explanation: Acetylcysteine is a mucolytic agent used to help thin and loosen mucus in the airways, making it easier to clear secretions. When administered via nebulization, it can stimulate increased mucus production, which may result in the client needing suctioning to remove the loosened secretions. This is a desired therapeutic effect because it helps clear the airways and improve lung function in clients with conditions like pneumonia.

D. Hypotension:

Hypotension is not a common or expected therapeutic response to acetylcysteine. It is important to monitor blood pressure during administration, but hypotension is not the primary effect of this medication.